NSE: GLAXO | BSE: 500660

Mid-range Performer

Download real time

2820.60 1.50 (0.05%)

46.83% Gain from 52W Low

57,375 NSE+BSE Volume

NSE 09 Sep, 2025 3:31 PM (IST)

47,782.7

Market Cap

High in industry

0.8

Beta 1Year

Very Low volatility

GlaxoSmithKline Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAXO, BSE:500660 GlaxoSmithKline Pharmaceuticals Ltd.

GlaxoSmithKline Pharmaceuticals Ltd.

16 Feb 2017

2820.60

0.05%

Glaxosmithkline Pharma Ltd Q3FY17 results comment

Results Update: GlaxoSmithKline Pharmaceut...

HDFC Securities

Revenue fell by 11.95% to Rs. 689.29 Cr in Q3FY17 when compared to the previous quarter. Also, it decreased by 5.63% when compared with Q3FY16.

Number of FII/FPI investors increased from 340 to 390 in Jun 2025 qtr.

GlaxoSmithKline Pharmaceuticals Ltd.

15 Feb 2017

2820.60

0.05%

Result Updates

Neutral: GlaxoSmithKline Pharmaceut...

Angel Broking

For 3QFY2017 Glaxo Pharmaceuticals (GSK) posted results lower than expectations on all fronts. In sales, the company posted sales of Rs689cr v/s Rs700cr expected, a yoy de-growth of 5.6%. On EBITDA front, the company posted EBITDA of 5.1% (v/s 9.1% expected) v/s 11.6% in 3QFY2016. Consequently, Adj. PAT came in at Rs40.8cr (v/s Rs78.4cr e..

GlaxoSmithKline Phar.. has an average target of 2800.00 from 2 brokers.

GlaxoSmithKline Pharmaceuticals Ltd.

09 Nov 2016, 12:00AM

2820.60

0.05%

Glaxosmithkline Pharma Ltd

Neutral: GlaxoSmithKline Pharmaceut...

Angel Broking

For 2QFY2017, sales stood at Rs783cr vs. Rs700cr expected and vs. Rs700cr in 2QFY2016, a yoy growth of 11.8%. On the operating front, the OPM came in at 15.9% vs. 17.2% in 2QFY2016 and vs. 17.0% expected. The company's OPM was impacted by other expenses, which grew by 40.5% yoy. Thus, the company posted an Adj. net profit of Rs98cr vs. Rs..

GlaxoSmithKline Phar.. has an average target of 2800.00 from 2 brokers.

GlaxoSmithKline Pharmaceuticals Ltd.

28 Jul 2016

2820.60

0.05%

GSK Pharma: Weak results- margin improvement is key

Neutral: GlaxoSmithKline Pharmaceut...

Motilal Oswal

GSK Pharma's (GLXO) 1QFY17 sales increased 10% YoY to INR6.9b (3% below estimate), while EBITDA declined 32% YoY to INR702m (26% below estimate) and PAT fell 23% YoY to INR723m (29% miss). Reported PAT included exceptional income of INR18m related to the sale of land at Mulund. Capacity constrains at Nasik facility, unavailability of quality third suppliers and policy actions have been the key issues for GSK over the past few quarters. Deal with Novartis boosts sales growth: Total sales growth of ~10% YoY includes ~4% growth from the vaccines asset sale agreement with Novartis...

Number of FII/FPI investors increased from 340 to 390 in Jun 2025 qtr.

GlaxoSmithKline Pharmaceuticals Ltd.

10 Jun 2016

2820.60

0.05%

Glaxosmithkline Pharma Ltd

Neutral: GlaxoSmithKline Pharmaceut...

Angel Broking

For 4QFY2016, GlaxoSmithKline Pharmaceuticals (GSK)'s sales rose by Rs686cr, up 11.8% yoy. On the operating front, the gross margin and the EBITDA margin came in at 55.0% and 17.8% respectively V/s 57.1% and 19.4% during the corresponding period of the previous year. The reported net profit for the quarter thus came in at Rs106cr V/s Rs10..

GlaxoSmithKline Pharmaceuticals Ltd. is trading above its 200 day SMA of 2712.2

GlaxoSmithKline Pharmaceuticals Ltd.

18 Feb 2016

2820.60

0.05%

Glaxosmithkline Pharma Ltd- Research Report

Neutral: GlaxoSmithKline Pharmaceut...

Angel Broking

For 3QFY2016, GlaxoSmithKline Pharmaceuticals (GSK Pharma) posted a disappointing operating performance. For the quarter, the company posted sales of Rs729cr (V/s Rs730cr expected), a growth of 12.8% yoy. On the operating front, the company posted a gross margin of 53.1% V/s 55.6% in the corresponding period of the previous year. The OPM came in at 14.1% V/s 17.0% during the corresponding period of previous year, mainly owing to lower gross margin on a yoy basis. This was against our expectations of 18.1%. Thus, the reported net profit came in at Rs82cr V/s Rs55cr in the corresponding period of last year. However, the Adj. net profit came in at Rs80cr V/s Rs45cr in 3QFY2015, a yoy growth of 76.4%. We remain Neutral on the stock. Results below our expectations: For 3QFY2016, the company posted a disappointing operating performance. For the quarter, the company posted sales of Rs729cr (V/s Rs730cr expected), a growth of 12.8% yoy. On the operating front, the company posted a gross margin of 53.1% V/s 55.6% in the corresponding period of the previous year. The OPM came in at 14.1% V/s 17.0% during the corresponding period of previous year, mainly owing to lower gross margin on a yoy...

GlaxoSmithKline Phar.. has an average target of 2800.00 from 2 brokers.

GlaxoSmithKline Pharmaceuticals Ltd.

11 Feb 2016

2820.60

0.05%

GSK Pharma: Q3FY16 Result Review-Margins Underperform on back of lower gross mar... (Feb 11, 2016)

Sell: GlaxoSmithKline Pharmaceut...

Karvy

GSK Pharma's total revenues increased by 13% YoY to Rs 7356 mn in Q3FY16 lower than our estimates of Rs 7513 mn. Operating margins decreased by 270bps YoY to 14.9% (lower than our estimate of 17.7%) on account of lower gross margins and CSR exps of Rs 136.7 mn.

Number of FII/FPI investors increased from 340 to 390 in Jun 2025 qtr.

Is GlaxoSmithKline Pharmaceuticals Ltd. worth buying?

124 Votes:

Buy 66.13%

Sell 20.97%

Hold 12.9%

RESEARCH REPORTS

Neutral SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf